BioTuesdays

Tag - H.C. Wainwright

Assembly Biosciences
Markets

HCW starts Assembly Biosciences at neutral; PT $3.50

H.C.Wainwright initiated coverage of Assembly Biosciences (NASDAQ:ASMB) with a “neutral” rating and price target of $3.50. The stock closed at $3.23 on Sept. 10. Assembly is focused on developing treatments for chronic...

September 13, 2021
Markets

HCW starts IVERIC Bio at buy; PT $20

H.C. Wainwright launched coverage of IVERIC Bio (NASDAQ:ISEE) with a “buy” rating and price target of $20. The stock closed at $9.07 on Aug. 18. Analyst Matthew Caufield writes that IVERIC’s retinal platform is...

August 19, 2021
Markets

HCW cuts Sesen Bio to neutral; withdraws PT

H.C. Wainwright downgraded Sesen Bio (NASDAQ:SESN) to “neutral” from “buy” and removed its price target after the company on Aug. 13 received a complete response letter from the FDA. The stock closed at $2.11 on Aug. 13...

August 16, 2021
BeyondSpring Logo
Markets

HCW ups BeyondSpring to buy from neutral; PT $100

H.C. Wainwright upgraded BeyondSpring (NASDAQ:BYSI) to “buy” from “neutral” with a price target of $100 after the company reported positive topline results from its DUBLIN-3 registrational trial of plinabulin in...

August 4, 2021
Axcella Logo
Markets

HCW starts Axcella Health at buy; PT $14

H.C. Wainwright initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $14 price target. The stock closed at $3.97 on July 2. Axcella Health is a clinical-stage biotechnology company pioneering a new...

July 6, 2021
Sutra-Biopharma-Logo
Markets

HCW starts Sutro Biopharma at buy; PT $35

H.C. Wainwright initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and price target of $35. The stock closed at $18.73 on June 17. “We believe Sutro Biopharma can continue to be a standout performer...

June 17, 2021
Markets

HCW starts Metacrine at buy; PT $15

H.C. Wainwright launched coverage of Metacrine (NASDAQ:MTCR) with a “buy” rating and $15 price target. The stock closed at $4.14 on June 11. Metacrine is a clinical-stage biopharmaceutical company focused on discovering...

June 14, 2021
Markets

HCW starts UNITY Biotechnology at buy; PT $12

H.C. Wainwright launched coverage of UNITY Biotechnology (NASDAQ:UBX) with a “buy” rating and $12 price target. The stock closed at $4.56 on June 4. UNITY is focusing on therapeutics addressing diseases of aging, while...

June 7, 2021
PDS Biotechnology Logo
Markets

HCW ups PDS Biotechnology PT to $20 from $8

H.C. Wainwright raised its price target for PDS Biotechnology (NASDAQ:PDSB) to $20 from $8 ahead of additional data being released at the ASCO meeting this weekend. The stock closed at $10.86 on June 1. “We believe that...

June 2, 2021
Markets

HCW starts Asensus Surgical at buy; PT $4

H.C. Wainwright launched coverage of Asensus Surgical (NYSE American:ASXC) with a “buy” rating and price target of $4. The stock closed at $2.03 on May 25. Asensus, a surgical robotics company, is digitizing laparoscopy...

May 26, 2021